Welcome!

News Feed Item

Developments and Trends in Influenza Therapeutics (Technical Insights)

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Developments and Trends in Influenza Therapeutics (Technical Insights)

Emerging Technology and Major Partnerships in Influenza Vaccines

Influenza is a burgeoning problem across the entire globe, there is an increased need for new therapeutic methods. A whole host of technology platforms are being utilized to create non egg based vaccines. The world has not seen an influenza pandemic, and in terms of historical occurrences, we are several years overdue of one. There is a critical need for a universal vaccine, that has the potential to prevent multiple strains of influenza, so that yearly vaccinations can be eliminated and healthcare costs can be reduced. The main focus of the research service features the influenza vaccine market and the types of emerging technologies as well as developing partnerships over 2010-2013.

Key Findings

1. The Influenza therapeutics industry can be split into two main segments the antiviral industry and the influenza vaccines industry. There is a lot of funding for these industries to ensure protection for the global population against seasonal and pandemic influenza. Companies are striving to cover everyone, including the high-risk groups, such as children below the age of 2, adults above the age of 65, and people with preexisting medical conditions.
2. The influenza vaccine industry is witnessing a shift from the conventional egg-based vaccine development methods to more novel approaches. Some of them being DNA-based, recombinant subunit-based and even microbial vector-based approaches. These approaches are proving to be more cost effective and seem to have a higher rate of mass production, which is crucial if an influenza pandemic surfaces.
3. Efforts are being directed toward covering a boarder spectrum of viral strains than those presently being covered by seasonal influenza vaccines. The FDA has approved quadrivalent vaccines for distribution during the 2013-2014 seasonal influenza which covers Xstrains. There has been an increase in collaborations for the development of these 'universal vaccines' across the globe.
4. Developing new modes of administration of influenza vaccines is also an avenue that is being heavily explored by large and small biotechnology companies. They aim to eliminate the need for a needle and make it less invasive; this seems to be the primary focus of most research efforts. Some of the more nascent forms of administrating vaccines are oral vaccines and vaccine patches.
5. Looking more into R&D in a geographic perspective, there is a lot of funding going into influenza therapeutics in the US. In Europe, there is greater focus of R&D on new antiviral drug therapies and less focus on the vaccine industry. There is increasing focus on R&D in Asia Pacific and various new developments have taken place on the vaccine front, especially in countries, such as Singapore and Australia.

Research Scope

Influenza is a form of viral infection that can spread rapidly between people. It affects almost every age group and tends to impact the economy due to a significant decrease in productivity when employed professionals take sick leave. Seasonal epidemics usually affect the northern hemisphere (temperate regions) during the winter months. According to the Centers for Disease Control (CDC), worldwide influenza affects about Xmillion people annually and causes anywhere between X to Xdeaths. Children below the age of two, senior citizens ( over 65 years) and people who already have medical aliments, fall under the high-risk group. Seasonal influenza can be prevented by annual vaccinations against the prevalent strains for that season.

Influenza strains tend to rapidly mutate, aiding them in gaining resistance against the influenza vaccinations and antiviral drugs. Scientists in university laboratories and pharmaceuticals are trying to develop universal vaccines, that will provide patients boarder coverage against multiple influenza strains.

Looking at the larger picture, the influenza therapeutics industry has been experiencing many crucial changes. There are quite a few technical and business challenges that require immediate attention. The healthcare industry in general is moving toward preventative treatment options. Vaccine improvements will benefit all age groups as well as people with pre-existing conditions. The target demographics for these vaccines will increase , subsequently reducing epidemics across the globe.
Referencing sources on previous pandemics that have occurred, an influenza pandemic is currently overdue, which is an important point to note, as challenges with regards to pandemic influenza vaccinations need to be addressed immediately, to stay abreast with the situation of a potential pandemic.

The research service covers the following:
• Captures technologies used for influenza therapeutics and highlights innovations in the influenza vaccines and antiviral industry Orientation of research for existing and emerging diseases.
• Outlines the research portfolio, key trends and addresses the key technical challenges and key market challenges, and key performance
• Identifies opportunities in the field of targeted drug delivery for emerging and existing applications
• Provides strategic insights by highlighting the key performance indicators in the influenza therapeutics industry
• Highlights partnerships/collaborations at a global level for enhancing the development of influenza vaccines and entering into the market
• Provides strategic recommendations and conclusions, for companies working on influenza therapeutics to identify areas of growth
• Analytical Hierarchy Process (AHP) that analyzes the current research portfolio adopted by most companies for existing and emerging diseases.

Influenza Therapeutics Snapshot

Market Overview
• The influenza therapeutics market is valued at more than US $6 billion. (Frost & Sullivan Research Services)
• The Influenza vaccines segment is the largest and is expected to be $X billion
• The market is dominated by prophylactic vaccines for seasonal influenza treatments.
• Trivalent intramuscular vaccines form the largest market share under prophylactic vaccines.
• It is projected that quadrivalent vaccines will start dominating the market over the next five to seven years.

Influenza Therapeutics Market
Influenza Vaccines: X%
Antiviral Drugs: X%

Technology Overview
Presently influenza vaccines are based of two forms. One is the inactivated form that is usually delivered as an injection and the live attenuated form, that is delivered intranasally. The inactivated form can be further spilt into X different segments--the whole virus vaccine, split virus vaccine, and the subunit vaccine. These conventional methods predominantly use an egg-based production methodology. The present technology trend is moving toward reducing the egg-based production approach and delving deeper into cell-based production approaches.
The cell-based approaches are still under development and do not have any standardized protocols. There is also a lot of government, and private funded research taking place in small biotechnology companies and universities that are focusing on innovating novel technology platforms to produce and manufacture influenza vaccines. The conventional methods of production are not cost effective and take a long time to produce, approximately 6 to 9 months is needed for a flu vaccine to become available to the end user population. These novel and nascent technologies are aimed at solving challenges involving high cost of production and reduce the time required for the vaccine to become available to the end users.

Influenza Overview

• Influenza, commonly known as 'flu' is a respiratory infection caused by RNA viruses in the Orthomxyoviridae family.
• It is divided into three subtypes A, B and C, based on antigenic and genetic differences in their hemagglutinin (HA) and neuraminidase (NA) glycoproteins present on the surface of the virus.
• Seasonal human influenza is caused by types A and B, whereas type C occurs rarely as a mild disease in children
• Currently, the H1N1, H3N2, H5N1 strains of influenza are prevalent in humans and extensive research is being undertaken for developing therapeutics against these strains.

Influenza Subtype A
• Most of the common influenza epidemics affecting the human population are predominantly caused by this particular subtype of influenza. They are constantly mutating due to antigenic shifts. Two very important proteins that are present on the viral surface are hemagglutinin (HA) and neuraminidase (NA). At present, there are around X different subtypes of HA and 9 forms of NA. This form of influenza tends to undergo both the antigenic drift as well as the antigenic shift.

Influenza Subtype B
• This genus of virus, tends to mutate at a much slower rate than the influenza virus A. But unfortunately, most vaccinations do not give lasting immunity for this strain due to the manner in which they mutate.
• Mutations also happen due to antigenic shifts similar to Influenza virus A . This genus is found only in humans unlike Influenza virus A.

Influenza Subtype C
• This is a lot rarer compare to influenza virus A & B, but it has also been known to cause some epidemics which can be severe in intensity.

Table of Contents

Executive Summary 4
•Key Findings 5
•Research Scope 6
•Segmentation of Influenza Therapeutics 7
•Influenza Therapeutics Snapshot 8

Technology Snapshot 9
•Influenza Overview 10

Strategic Assessment of Industry Environment 11
•R& D Portfolio Analysis - Vaccines 12
• By Technology 13
• By Mode of Administration 19
•R& D Portfolio Analysis - Antivirals 20
•By Technology 21
•Industry Value Chain 22
•Stakeholder Overview 23
•Industry Participants -- By Technology 25
•Research Orientation 28
•Geographic Overview 30

Partnership & Alliances 32

R&D Budgetary Analysis 40

Environmental Analysis 48
•Technology Challenges 50
•Market Challenges 53

Strategic Evaluation of Research and Development Portfolio 57
•AHP – Analytical Hierarchy Process Based Tree 58

Contacts, Patents & DSD Tables 65

Appendix 77

The Frost & Sullivan Story 81

Read the full report:
Developments and Trends in Influenza Therapeutics (Technical Insights)
http://www.reportbuyer.com/pharma_healthcare/treatments/developments_trends_influenza_therapeutics_technical_insights.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus o...
Big Data engines are powering a lot of service businesses right now. Data is collected from users from wearable technologies, web behaviors, purchase behavior as well as several arbitrary data points we’d never think of. The demand for faster and bigger engines to crunch and serve up the data to services is growing exponentially. You see a LOT of correlation between “Cloud” and “Big Data” but on Big Data and “Hybrid,” where hybrid hosting is the sanest approach to the Big Data Infrastructure pro...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, will explore the value of Kibana 4 for log analysis and will give a real live, hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He will examine three use cases: IT operations, business intelligence, and security and compliance. This is a hands-on session that will require participants to bring their own laptops, and we will provide the rest.
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In his General Session at 16th Cloud Expo, David Shacochis, host of The Hybrid IT Files podcast and Vice President at CenturyLink, investigated three key trends of the “gigabit economy" though the story of a Fortune 500 communications company in transformation. Narrating how multi-modal hybrid IT, service automation, and agile delivery all intersect, he will cover the role of storytelling and empathy in achieving strategic alignment between the enterprise and its information technology.
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists peeled away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud enviro...
In their general session at 16th Cloud Expo, Michael Piccininni, Global Account Manager - Cloud SP at EMC Corporation, and Mike Dietze, Regional Director at Windstream Hosted Solutions, reviewed next generation cloud services, including the Windstream-EMC Tier Storage solutions, and discussed how to increase efficiencies, improve service delivery and enhance corporate cloud solution development. Michael Piccininni is Global Account Manager – Cloud SP at EMC Corporation. He has been engaged in t...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
"LinearHub provides smart video conferencing, which is the Roundee service, and we archive all the video conferences and we also provide the transcript," stated Sunghyuk Kim, CEO of LinearHub, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
A look across the tech landscape at the disruptive technologies that are increasing in prominence and speculate as to which will be most impactful for communications – namely, AI and Cloud Computing. In his session at 20th Cloud Expo, Curtis Peterson, VP of Operations at RingCentral, will highlight the current challenges of these transformative technologies and share strategies for preparing your organization for these changes. This “view from the top” will outline the latest trends and developm...
Things are changing so quickly in IoT that it would take a wizard to predict which ecosystem will gain the most traction. In order for IoT to reach its potential, smart devices must be able to work together. Today, there are a slew of interoperability standards being promoted by big names to make this happen: HomeKit, Brillo and Alljoyn. In his session at @ThingsExpo, Adam Justice, vice president and general manager of Grid Connect, will review what happens when smart devices don’t work togethe...
When you focus on a journey from up-close, you look at your own technical and cultural history and how you changed it for the benefit of the customer. This was our starting point: too many integration issues, 13 SWP days and very long cycles. It was evident that in this fast-paced industry we could no longer afford this reality. We needed something that would take us beyond reducing the development lifecycles, CI and Agile methodologies. We made a fundamental difference, even changed our culture...